Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte

[1]  M. Biffi,et al.  The value of ECG changes in risk stratification of COVID‐19 patients , 2021, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[2]  A. Griffiths,et al.  A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent , 2021, Nature structural & molecular biology.

[3]  V. Babenko,et al.  Free SARS-CoV-2 Spike Protein S1 Particles May Play a Role in the Pathogenesis of COVID-19 Infection , 2020, Biochemistry (Moscow).

[4]  G. De Luca,et al.  Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry , 2020, Cardiovascular Diabetology.

[5]  N. Al-Daghri,et al.  Prevalence of diabetes, management and outcomes among Covid-19 adult patients admitted in a specialized tertiary hospital in Riyadh, Saudi Arabia , 2020, Diabetes Research and Clinical Practice.

[6]  Qiang Zhou,et al.  Engineered trimeric ACE2 binds viral spike protein and locks it in “Three-up” conformation to potently inhibit SARS-CoV-2 infection , 2020, Cell research.

[7]  G. Martinelli,et al.  ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients , 2020, Cell transplantation.

[8]  T. Kortemme,et al.  Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.

[9]  R. Holman,et al.  Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II) , 2020, Cardiovascular Diabetology.

[10]  S. Rizzo,et al.  Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study , 2020, European heart journal.

[11]  D. Kell,et al.  Prevalence of readily detected amyloid blood clots in ‘unclotted’ Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report , 2020, Cardiovascular Diabetology.

[12]  Jeremy L. Praissman,et al.  Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor , 2020, Cell Host and Microbe.

[13]  M. Biffi,et al.  Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients , 2020, Frontiers in Pharmacology.

[14]  P. Kirchhof,et al.  Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. , 2020, JAMA cardiology.

[15]  D. Giugliano,et al.  Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies , 2020, Cardiovascular Diabetology.

[16]  Oliver Schnell,et al.  Issues for the management of people with diabetes and COVID-19 in ICU , 2020, Cardiovascular Diabetology.

[17]  G. Paolisso,et al.  Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19 , 2020, Cardiovascular Diabetology.

[18]  M. Falleni,et al.  Evidence of SARS-CoV-2 Transcriptional Activity in Cardiomyocytes of COVID-19 Patients without Clinical Signs of Cardiac Involvement , 2020, medRxiv.

[19]  Kipp W. Johnson,et al.  Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection , 2020, Journal of the American College of Cardiology.

[20]  A. Frangakis,et al.  SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes , 2020, bioRxiv.

[21]  G. Paolisso,et al.  Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients , 2020, Diabetes & Metabolism.

[22]  P. Valensi,et al.  Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era , 2020, Diabetes Care.

[23]  S. Cao,et al.  Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 , 2020, European heart journal.

[24]  Huihui Ren,et al.  Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19 , 2020, Cardiovascular Diabetology.

[25]  R. Faller,et al.  Development and simulation of fully glycosylated molecular models of ACE2-Fc fusion proteins and their interaction with the SARS-CoV-2 spike protein binding domain , 2020, bioRxiv.

[26]  Asif Shajahan,et al.  Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2 , 2020, bioRxiv.

[27]  A. Brufsky.  Hyperglycemia, hydroxychloroquine, and the COVID‐19 pandemic , 2020, Journal of medical virology.

[28]  T. Walther,et al.  Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts , 2020, European heart journal.

[29]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[30]  Yi Feng,et al.  The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2 , 2020, Cardiovascular research.

[31]  Mohammad Madjid,et al.  Potential Effects of Coronaviruses on the Cardiovascular System: A Review. , 2020, JAMA cardiology.

[32]  W. Gong,et al.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.

[33]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[34]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[35]  C. Napoli,et al.  Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients. , 2020, Journal of the American College of Cardiology.

[36]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[37]  Qianyun Liu,et al.  Emerging coronaviruses: Genome structure, replication, and pathogenesis , 2020, Journal of medical virology.

[38]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[39]  2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018 , 2017, Diabetes Care.

[40]  R. Schasfoort,et al.  Rapid screening of IgG quality attributes – effects on Fc receptor binding , 2017, FEBS open bio.

[41]  A. Della Corte,et al.  Acute hemodynamic and functional effects of surgical ventricular restoration and heart transplantation in patients with ischemic dilated cardiomyopathy. , 2008, The Journal of thoracic and cardiovascular surgery.

[42]  Su-Yen Goh,et al.  The role of advanced glycation end products in progression and complications of diabetes , 2008 .

[43]  J. Luban.  SARS-CoV-2 , 2020 .

[44]  Simon Gibbs,et al.  [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. , 2015, Kardiologia polska.

[45]  M. Cooper,et al.  Mechanisms of diabetic complications. , 2013, Physiological reviews.

[46]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[47]  A. Della Corte,et al.  Determinants and prognostic value of ischemic necrosis in early biopsies following heart transplant , 2000, Heart and Vessels.